EGFR and non-small cell lung carcinoma: Compared to first-generation and second-generation EGFR TKIs, furmonertinib has better penetration across the blood-brain barrier and demonstrates efficacy in treating central nervous system metastases in non-small cell lung cancer, showing a favorable response rate.